Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 1, 2005, Pages 395-402

  Bradbury, Margaret J ^a,b   Campbell, Una ^a,c   Giracello, Darlene ^a,d   Chapman, Deborah ^a   King, Chris ^a,e   Tehrani, Lida ^a   Cosford, Nicholas D P ^a   Anderson, Jeff ^a,f   Varney, Mark A ^a,c   Strack, Alison M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NEUROCRINE BIOSCIENCES INC   (United States)

^c SUNOVION PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e R W JOHNSON PHARMACEUTICAL RES I   (United States)

^f Cypress Bioscience Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; DEXFEN; DEXFENFLURAMINE; DRUG VEHICLE; INSULIN; LEPTIN; METABOTROPIC RECEPTOR 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE; ARTICLE; BODY WEIGHT; CALORIE; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENERGY BALANCE; ENERGY EXPENDITURE; FEEDING; FOOD DEPRIVATION; FOOD INTAKE; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; LIPID DIET; MALE; MOUSE; NEUROTRANSMISSION; NIGHT; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; APPETITE; APPETITE DEPRESSANTS; DIETARY FATS; EATING; ENERGY METABOLISM; FENFLURAMINE; FOOD DEPRIVATION; MALE; MICE; MICE, KNOCKOUT; OBESITY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; REWARD; THIAZOLES; WEIGHT GAIN;

EID: 20144364615     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.076406     Document Type: Article

References (38)

1. Anderson JJ, Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Roppe J, King C, Cosford NDP, and Varney MA (2003) In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2- ylethynyl)pyridine). Eur J Pharmacol 473:35-40.
2. Anderson JJ, Rao SP, Rowe B, Giracello DR, Holtz G, Chapman DF, Tehrani L, Bradbury MJ, Cosford NDP, and Varney MA (2002) [3H]Methoxymethyl-3-[(2- methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 303:1044-1051.
3. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, and Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106.
4. Bäckström P, Bachteler D, Koch S, Hyytiä P, and Spanagel R (2004) mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 29:921-928.
5. Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Schaffhauser H, Rao SP, Varney MA, and Anderson JJ (2003) Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems. Neuropharmacology 44:562-572.
6. Busse C, Brodkin J, Tattersall D, Anderson J, Warren N, Tehrani L, Bristow L, Varney M, and Cosford N (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29:1971-1979.
7. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39:215-231.
8. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, and Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4:873-874.
9. Clegg DJ, Benoit SC, Air EL, Jackman A, Tso P, D'Alessio D, Woods SC, and Seeley RJ (2003) Increased dietary fat attenuates the anorexic effects of intracerebroventricular injections of MTII. Endocrinology 144:2941-2946.
10. Cohen C, Perrault G, Voltz C, Steinberg R, and Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451-463.
11. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
12. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, et al. (2003) 3-[(2-Methyl-1,3- thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206.
13. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, et al. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
14. Ghasemzadeh MB, Nelson LC, Lu XY, and Kalivas PW (1999) Neuroadaptations in ionotropic and metabotropic glutamate receptor mRNA produced by cocaine treatment. J Neurochem 72:157-165.
15. Golembiowska K, Konieczny J, Wolfarth S, and Ossowska K (2003) Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology 45:484-492.
16. Halford JCG, Wanninayake SCD, and Blundell JE (1998) Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159-168.
17. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, and Kalra PS (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20:68-100.
18. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, and Zhang M (2002) Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76:365-377.
19. Kelley AE and Berridge KC (2002) The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306-3311.
20. Kerner JA, Standaert DG, Penney JB Jr, Young AB, and Landwehrmeyer GB (1997) Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex and hippocampus. Brain Res Mol Brain Res 48:259-269.
21. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, and Roder JC (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17:5196-5205.
22. Mao L and Wang JQ (2001) Differentially altered mGluR1 and mGluR5 mRNA expression in rat caudate nucleus and nucleus accumbens in the development and expression of behavioral sensitization to repeated amphetamine administration. Synapse 41:230-240.
23. McGeehan AJ and Olive MF (2003) The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 47:240-242.
24. Mock S, Shen X, and Tamvakopoulos C (2002) Determination of melanotan-II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration. Rapid Commun Mass Spectrom 16:2142-2147.
25. Morikawa H, Khodakhah K, and Williams JT (2003) Two intracellular pathways mediate metabotropic glutamate receptor-induced Ca2+ mobilization in dopamine neurons. J Neurosci 23:149-157.
26. O'Meara GF, Newman RJ, Reynolds DS, Bristow LJ, and Dawson GR (2002) Behavioural evaluation of mGluR5 knock-out mouse. FENS Forum 1:A087.
27. Paterson N, Semenova S, Gasparini F, and Markou A (2003) The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 167:257-264.
28. Pierce RC, Bell K, Duffy P, and Kalivas PW (1996) Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J Neurosci 16:1550-1560.
29. Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B, Tatarczynska E, Chojnacka-Wojcik E, and Wieronska J (2002) Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43:181-187.
30. Popik P and Wrobel M (2002) Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology 43:1210-1217.
31. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, and Soubrie P (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-R353.
32. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, and Olney JW (1995) Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355:455-469.
33. Salamone JD and Correa M (2002) Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3-25.
34. Spooren WP, Gasparini F, Salt TE, and Kuhn R (2001) Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 22:331-337.
35. Taber MT and Fibiger HC (1997) Feeding-evoked dopamine release in the nucleus, accumbens: regulation by glutamatergic mechanisms. Neuroscience 76:1105-1112.
36. Trivedi P, Jiang M, Tamvakopoulos C, Shen X, Yu H, Mock S, Fenyk-Melody J, Van der Ploeg L, and Guan X (2003) Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain Res 977:221-230.
37. van den Pol AN, Romano C, and Ghosh P (1995) Metabotropic glutamate receptor mGluR5 subcellular distribution and developmental expression in hypothalamus. J Comp Neurol 362:134-150.
38. Vickers S, Webster L, Wyatt A, Dourish C, and Kennett G (2003) Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167:103-111.